Clinical Trials

Phase 3 Active not recruiting

Breast Neoplasms, Neoplasms

NCT00433420 2024-05-08

Combination Chemotherapy With or Without Fluorouracil and/or Pegfilgrastim in Treating Women With Node-Positive Breast Cancer

2,000 enrolled

Phase 3 Active not recruiting

Breast Neoplasms

NCT01996267 2024-03-29

TRAIN-2

437 enrolled

Breast Neoplasms

NCT00630032 2024-02-21

TavIx

762 enrolled 14 charts

Breast Neoplasms

NCT00309478 2023-06-29

Randomized Study Comparing CMF and Goserelin + Tamoxifen in Premenopausal Receptor-positive Patients

1,099 enrolled

Breast Neoplasms

NCT00121992 2023-04-04

Docetaxel, Doxorubicin (A), Cyclophosphamide (C) (TAC) vs 5-Fluorouracil, A, C (5FAC) Breast Cancer Adjuvant Treatment

1,060 enrolled 20 charts

Breast Neoplasms

NCT00129389 2023-03-07

FAC Versus FAC Plus Weekly Paclitaxel as Adjuvant Treatment of Node Negative High Risk Breast Cancer Patients

1,925 enrolled 19 charts

Breast Neoplasms

NCT00129922 2023-03-06

Fluorouracil, Epirubicin, and Cyclophosphamide Alone or Followed by Paclitaxel for Early Breast Cancer

1,289 enrolled

Breast Neoplasms

NCT00087178 2022-08-11

Comparison of Two Combination Chemotherapy Regimens in Treating Women With Breast Cancer

2,722 enrolled 14 charts

Breast Neoplasms

NCT01966471 2022-06-14

A Study of Trastuzumab Emtansine (Kadcyla) Plus Pertuzumab (Perjeta) Following Anthracyclines in Comparison With Trastuzumab (Herceptin) Plus Pertuzumab and a Taxane Following Anthracyclines as Adjuvant Therapy in Participants With Operable HER2-Positive Primary Breast Cancer

1,846 enrolled 19 charts

Breast Neoplasms

NCT00309569 2020-10-14

Randomized Study Comparing Pre- and Postoperative vs. Conventional Adjuvant Treatment in Receptor-negative Patients

429 enrolled

Breast Neoplasms

NCT00014222 2020-10-05

Combination Chemotherapy With or Without Colony-stimulating Factors in Treating Women With Breast Cancer

2,104 enrolled 11 charts

Breast Neoplasms

NCT00625898 2020-09-10

BETH

Phase 3 Terminated

3,509 enrolled

Breast Neoplasms

NCT04031703 2020-04-24

Study Comparing Paclitaxel Plus Carboplatin Versus Anthracyclines Followed by Docetaxel as Adjuvant Chemotherapy for Triple Negative Breast Cancer (PATTERN)

647 enrolled

Breast Neoplasms

NCT00002542 2020-04-01

Tamoxifen in Treating Women With High-Risk Breast Cancer

672 enrolled

Breast Neoplasms

NCT02879513 2020-03-23

Trial of Adjuvant Chemotherapy in Breast Cancer Patients With Pathological Partial Response and Complete Response to Neoadjuvant Chemotherapy

290 enrolled

Carcinoma, Ductal, Breast, Inflammatory Breast Neoplasms

NCT04127019 2020-02-26

Adjuvant 6 Cycles of Docetaxel and Cyclophosphamide or 3 Cycles of Cyclophosphamide/Epirubicin/Fluorouracil Followed by 3 Cycles of Docetaxel Versus 4 Cycles of Epirubicin and Cyclophosphamide Followed by Weekly Paclitaxel in Operable Breast Cancer (MASTER)

2,079 enrolled

Primary Breast Cancer

NCT02115204 2019-10-03

4 x Epirubicin, Cyclophosphamide, Followed by 4 x Docetaxel Versus 6 x CMF / 6 x CEF

2,011 enrolled

Breast Neoplasms

NCT02995772 2019-06-19

Neoadjuvant Hormonal Therapy Compared to Neoadjuvant Chemotherapy in Stage IIIB/C and IV Breast Cancer Patients

122 enrolled

Breast Neoplasms

NCT03888677 2019-03-28

Dose-adjusted Adjuvant FEC Compared to Standard FEC for Breast Cancer

1,535 enrolled

Breast Neoplasms

NCT00301925 2018-08-08

TACT2

4,400 enrolled

Breast Neoplasms, Breast Neoplasms, Male

NCT00950300 2018-01-23

A Study to Compare Subcutaneous (SC) Versus Intravenous (IV) Administration of Herceptin (Trastuzumab) in Women With Human Epidermal Growth Factor Receptor (HER) 2-Positive Early Breast Cancer

596 enrolled 31 charts 2 FDA

Breast Neoplasms

NCT02980965 2017-11-13

Neoadjuvant Chemo-endocrine Therapy Versus Chemotherapy Alone in ER-positive, HER2-negative Breast Cancer

249 enrolled

Breast Neoplasms

NCT02001506 2017-08-29

Neo-shorter

250 enrolled

Breast Neoplasms

NCT01222052 2017-06-26

NNBC3-Europe

4,150 enrolled

Breast Neoplasms

NCT00331097 2017-03-28

ELDA: Elderly Breast Cancer - Docetaxel in Adjuvant Treatment

300 enrolled

Breast Neoplasms

NCT00544232 2016-02-15

Preoperative Epirubicin Paclitaxel Aranesp Study (PREPARE)

720 enrolled

Breast Neoplasms

NCT02450058 2015-05-21

MIG5

1,055 enrolled

Breast Neoplasms

NCT00615602 2015-03-04

Six vs 12 Months of Trastuzumab With Docetaxel Following FEC as Adjuvant Treatment in N+ Breast Cancer

489 enrolled

Breast Neoplasms

NCT00002870 2014-12-16

High Dose Chemotherapy Plus Peripheral Stem Cell Transplantation Compared With Standard Therapy in Treating Women With Locally Recurrent or Metastatic Breast Cancer

180 enrolled

Breast Neoplasms

NCT00053911 2014-12-16

Combination Chemotherapy Compared With Observation After Surgery in Treating Women With Relapsed Nonmetastatic Breast Cancer

Phase 3 Terminated

Breast Neoplasms

NCT01985724 2014-05-14

Sequential Administration of FE75C and Docetaxel Versus Docetaxel/Cyclophosphamide in HER-2 Negative, Node Positive Breast Cancer

650 enrolled

Breast Neoplasms

NCT00003577 2013-12-19

Combination Chemotherapy With or Without Epirubicin in Treating Women With Stage I or Stage II Breast Cancer

2,000 enrolled

Breast Neoplasms

NCT00003893 2013-12-19

Adjuvant Chemotherapy Plus Radiation Therapy in Treating Women With Early-Stage Breast Cancer

2,250 enrolled

Breast Neoplasms

NCT00005581 2013-12-18

Combination Chemotherapy in Treating Women With Stage II or Stage III Breast Cancer

Breast Neoplasms

NCT00002579 2013-11-06

Tamoxifen Following Combination Chemotherapy in Treating Women With Operable Invasive Breast Cancer

2,000 enrolled

Breast Neoplasms

NCT00002580 2013-11-06

Tamoxifen, Ovarian Ablation, and/or Combination Chemotherapy in Treating Premenopausal Women With Stage I, Stage II, or Stage IIIA Invasive Breast Cancer

Breast Neoplasms

NCT00002581 2013-11-06

Tamoxifen With or Without Combination Chemotherapy in Treating Postmenopausal Women With Operable Invasive Breast Cancer

Breast Neoplasms

NCT00002755 2013-11-06

Standard Chemotherapy Compared With High-Dose Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Women With Breast Cancer

600 enrolled

Breast Neoplasms

NCT00003012 2013-11-06

Combination Chemotherapy Following Surgery in Treating Women With Early Stage Breast Cancer

Breast Neoplasms

NCT00003680 2013-11-06

Standard Chemotherapy Compared With High-Dose Chemotherapy Plus Peripheral Stem Cell Transplant in Treating Women With Advanced or Inflammatory Breast Cancer

300 enrolled

Breast Neoplasms, Inflammatory Breast Neoplasms

NCT00017095 2013-10-24

Biomarker (p53 Gene) Analysis and Combination Chemotherapy Followed by Radiation Therapy and Surgery in Treating Women With Large Operable or Locally Advanced or Inflammatory Breast Cancer

1,856 enrolled

Breast Neoplasms, Inflammatory Breast Neoplasms

NCT00003013 2013-09-17

Chemotherapy Plus Surgery in Treating Women With Breast Cancer

450 enrolled

Breast Neoplasms

NCT00963729 2013-08-12

Chemotherapy or Letrozole Before Surgery in Treating Postmenopausal Women With Breast Cancer That Can Be Removed By Surgery

756 enrolled

Breast Neoplasms

NCT00629278 2013-08-07

Combination Chemotherapy and Trastuzumab in Treating Women With Stage I, Stage II, or Stage III HER2-Positive Breast Cancer

2,500 enrolled

Breast Neoplasms

NCT00002582 2013-08-02

Tamoxifen, Ovarian Ablation, and/or Chemotherapy in Treating Women With Stage I, Stage II, or Stage IIIA Breast Cancer

6,000 enrolled

Breast Neoplasms

NCT00002696 2013-08-02

Combination Chemotherapy in Treating Women With Stage III Breast Cancer

Phase 3 Suspended

Breast Neoplasms

NCT01031030 2013-08-02

Cyclophosphamide, Methotrexate, and Fluorouracil, With or Without Epirubicin Hydrochloride, in Treating Women Who Have Undergone Surgery for Breast Cancer (Group III Closed to New Patients as of 12/7/2009)

800 enrolled

Breast Neoplasms

NCT00054587 2013-07-19

Combination Chemotherapy With or Without Trastuzumab in Treating Women With Breast Cancer

3,010 enrolled